Invega(paliperidone)
Byannli, Erzofri, Invega, Paliperidone, Trevicta, Xeplion (paliperidone) is a small molecule pharmaceutical. Paliperidone was first approved as Invega on 2006-12-19. It is used to treat bipolar disorder, depressive disorder, schizophrenia, and schizophrenia spectrum and other psychotic disorders in the USA. It has been approved in Europe to treat psychotic disorders and schizophrenia.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| mental disorders | D001523 |
Trade Name
FDA
EMA
Invega, Invega hafyera, Invega sustenna, Paliperidone (discontinued: Invega, Paliperidone)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Paliperidone
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| INVEGA | Johnson & Johnson | N-021999 RX | 2006-12-19 | 3 products, RLD |
Show 1 discontinued
Paliperidone palmitate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| INVEGA TRINZA | Johnson & Johnson | N-207946 RX | 2015-05-18 | 4 products, RLD, RS |
| INVEGA HAFYERA | Johnson & Johnson | N-207946 RX | 2021-08-30 | 2 products, RLD |
| INVEGA SUSTENNA | Johnson & Johnson | N-022264 RX | 2009-07-31 | 5 products, RLD |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| erzofri extended-release | New Drug Application | 2025-03-18 |
| invega | New Drug Application | 2025-02-06 |
| invega hafyera | New Drug Application | 2025-02-18 |
| invega sustenna | New Drug Application | 2025-02-14 |
| invega trinza | New Drug Application | 2025-02-14 |
| paliperidone | ANDA | 2025-03-29 |
| paliperidone palmitate | Export only | 2024-01-09 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
PALIPERIDONE PALMITATE, INVEGA HAFYERA, JANSSEN PHARMS | |||
| 2024-08-30 | NS | ||
PALIPERIDONE PALMITATE, INVEGA TRINZA, JANSSEN PHARMS | |||
| 2024-08-30 | NS | ||
Patent Expiration
HCPCS
Code | Description |
|---|---|
| J2426 | Injection, paliperidone palmitate extended release, 1 mg |
Clinical
Clinical Trials
210 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schizophrenia | D012559 | EFO_0000692 | F20 | 40 | 15 | 50 | 47 | 30 | 179 |
| Psychotic disorders | D011618 | — | F20.81 | 10 | 3 | 8 | 13 | 8 | 41 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | 3 | 1 | 4 | 4 | 3 | 14 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 3 | — | 4 | 2 | 5 | 14 |
| Recurrence | D012008 | — | — | — | — | 5 | 1 | 2 | 8 |
| Schizophrenia spectrum and other psychotic disorders | D019967 | — | — | 2 | — | — | 2 | 2 | 6 |
| Depression | D003863 | — | F33.9 | 1 | — | 1 | 3 | — | 5 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 1 | — | — | 2 | — | 3 |
| Weight gain | D015430 | — | — | — | 1 | — | 1 | — | 2 |
| Drug therapy | D004358 | — | — | — | 1 | 1 | 1 | — | 2 |
Show 20 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mood disorders | D019964 | EFO_0004247 | F30-F39 | 3 | — | 2 | — | — | 5 |
| Psychotic affective disorders | D000341 | — | F39 | 1 | — | 1 | — | — | 2 |
| Mania | D000087122 | — | F30 | — | — | 1 | — | 1 | 2 |
| Heroin dependence | D006556 | EFO_0004240 | — | — | — | 1 | — | — | 1 |
| Amphetamine-related disorders | D019969 | EFO_0004701 | F15 | — | — | 1 | — | — | 1 |
| Dementia | D003704 | EFO_0003862 | F03 | — | — | 1 | — | — | 1 |
| Psychophysiologic disorders | D011602 | — | F45.9 | — | — | 1 | — | — | 1 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 1 | — | — | 1 |
| Somatoform disorders | D013001 | — | F45 | — | — | 1 | — | — | 1 |
| Shared paranoid disorder | D012753 | — | F24 | — | 1 | 1 | — | — | 1 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cognitive dysfunction | D060825 | — | G31.84 | — | 1 | — | — | — | 1 |
| Accelerated idioventricular rhythm | D016170 | — | — | — | 1 | — | — | — | 1 |
| Anhedonia | D059445 | — | R45.84 | — | 1 | — | — | — | 1 |
| Dual (psychiatry) diagnosis | D017831 | — | — | — | 1 | — | — | — | 1 |
| Obsessive-compulsive disorder | D009771 | EFO_0004242 | F42 | — | 1 | — | — | — | 1 |
| Compulsive personality disorder | D003193 | — | F60.5 | — | 1 | — | — | — | 1 |
| Sleep initiation and maintenance disorders | D007319 | — | F51.01 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schizotypal personality disorder | D012569 | — | F21 | 1 | — | — | — | — | 1 |
| Immunoassay | D007118 | — | — | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Central nervous system diseases | D002493 | — | G96.9 | 1 | — | — | — | — | 1 |
| Nervous system diseases | D009422 | — | G00-G99 | 1 | — | — | — | — | 1 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | — | N19 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | — | 1 | 1 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 1 | 1 |
| Emergencies | D004630 | — | — | — | — | — | — | 1 | 1 |
| Medication adherence | D055118 | EFO_0006344 | — | — | — | — | — | 1 | 1 |
| Delusions | D003702 | — | — | — | — | — | — | 1 | 1 |
| Paranoid schizophrenia | D012563 | — | F20.0 | — | — | — | — | 1 | 1 |
| Breast feeding | D001942 | — | — | — | — | — | — | 1 | 1 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 1 | 1 |
| Periodontal diseases | D010510 | — | K05.6 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Paliperidone |
| INN | paliperidone |
| Description | 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one is a member of the class of pyridopyrimidines that is 9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2. It is a member of 1,2-benzoxazoles, a heteroarylpiperidine, an organofluorine compound, a pyridopyrimidine and a secondary alcohol. |
| Classification | Small molecule |
| Drug class | antipsychotics (risperidone type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O |
Identifiers
| PDB | — |
| CAS-ID | 1020719-55-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1621 |
| ChEBI ID | 83804 |
| PubChem CID | 115237 |
| DrugBank | DB01267 |
| UNII ID | 838F01T721 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Invega – Alkermes
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Invega – Johnson & Johnson
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Paliperidone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,024 documents
View more details
Safety
Black-box Warning
Black-box warning for: Erzofri extended-release, Invega, Invega hafyera, Invega sustenna, Invega trinza, Paliperidone
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
50,513 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use